The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

Discover AstraZeneca's groundbreaking patent for dual-target antibody molecules aimed at EGFR and c-Met, paving the way for innovative cancer therapies.

The EGF receptor (EGFR) was the first receptor to be proposed for cancer therapy and two EGFR-targeted pharmacologic approaches have been successfully developed: monoclonal antibodies (mAbs ...

One molecular target of particular relevance to lung cancer pathogenesis is the EGF receptor (EGFR). The EGFR (also known as ErbB-1/HER1) is a 170-kDa transmembrane glycoprotein that consists of ...

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

Rybrevant (amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally ...

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

The presentation will be available on Azitra’s website at https://ir.azitrainc.com/news-events/presentations.

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, ...